Full Breakdown
Congo’s Fastest-Growing Ebola Outbreak Spurs Emergency Vaccination of Front-Line Workers
By Drooid · · How we work
Core Event: Emergency Rollout of Ervebo to Health Workers
The campaign targets 20,000 workers in Ituri and North Kivu and will run for six to nine months. It uses Merck’s Ervebo vaccine, licensed for the Zaire strain and deployed under compassionate use while its effectiveness against the Bundibugyo variant is studied.
Background & Context
The outbreak was declared on May 15 after laboratory confirmation of the Bundibugyo virus. Retrospective data show the first symptomatic case—a health worker from Mongbwalu—appeared around April 24-25, with community fear reported on March 30, 2026. Early WHO and Africa CDC alerts arrived on May 5, but a three-week gap before confirmation allowed spread. The event is now the largest in DRC history and the fastest-spreading Ebola outbreak worldwide.
Data & Statistics
- Confirmed cases: government figures list 7,541 cases with 3,639 deaths; WHO reports “more than 7,000 cases” across seven provinces as of September 11.
- Vaccine stock: WHO approved 70,000 doses of Ervebo, allocating 50,000 for front-line workers and 20,000 for a trial on Bundibugyo protection.
- Economic impact: UNDP estimates potential losses of over $1 billion in real GDP and 55,000 jobs if the outbreak persists, with 985,000 people at risk of extreme poverty.
Official Statements & Responses
- Maj. Gen. Gaby Kasongo Mulumba, military governor of Ituri, called the vaccination drive a “collective duty to protect life.”
- WHO Director-General Tedros Adhanom Ghebreyesus noted “encouraging signs” in Ituri but warned the epidemic is “far from over.”
- WHO acting director Van Kerkhove said, “We have many, many months ahead of us.”
- WHO Regional Director for Africa Mohamed Janabi said genome sequencing suggests the outbreak may have begun “as early as February 2026.”
On-the-Ground Reports
Health workers in Bunia reported mandatory vaccination; some had received Ervebo during earlier outbreaks. UN Women noted that 54 % of confirmed patients are women, and women and girls make up 51 % of cases aged 10-17, reflecting their caregiving roles.
Conflicting Reports & Gaps
- Case counts: Government data (7,541) differ from WHO’s “more than 7,000,” creating uncertainty about scale.
- Vaccine efficacy: Ervebo is licensed for Zaire-type Ebola; its protection against Bundibugyo remains unproven pending trial results.
- Early transmission: Genome analyses point to a possible start in February, yet the official declaration came on May 15, leaving a reporting gap.
Verbatim Quotes
- “Although ERVEBO was not originally developed to protect against Bundibugyo, preliminary data suggest that it may offer some degree of protection against the virus,” — Guyguy Manangama, MSF epidemiologist
- “The outbreak is not shrinking, it is moving: South Ubangi has become the seventh affected province, while North Kivu now accounts for nearly half of all newly confirmed cases, with test positivity rising sharply in recent days,” — Anthony Kergosien
- “Several deaths were reported following high fevers, and the victims often showed traces of blood around various body orifices,” — Dieudonne Lossa Dekhana
What’s Next
The BRAVO observational study launched on September 19, 2026, will follow vaccinated workers for at least six months to generate real-world effectiveness data. A mid-to-late-stage trial led by Congo’s National Institute for Biomedical Research with partners such as Moderna and the University of Oxford is slated to begin soon. WHO’s six-month response plan seeks $1.3 billion for testing, treatment, surveillance, logistics and community engagement.